Mid cap infrastructure construction stock Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 7.23% after being trashed in an article by an apparent�short seller posted on Seeking Alpha, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like Jacobs Engineering Group Inc (NYSE: JEC), KBR, Inc (NYSE: KBR) and First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM).
What is the Chicago Bridge & Iron Company N.V.?Founded in 1889 in Chicago, mid cap Chicago Bridge & Iron Company N.V. calls itself the most complete energy infrastructure focused company in the world and a major provider of government services. In fact, Chicago Bridge & Iron Company N.V. is one of the most complete providers of a wide range of services including design, engineering, construction, fabrication, maintenance and environmental services.
5 Best Cheap Stocks To Buy For 2015: McMoRan Exploration Company (MMR)
McMoRan Exploration Co. engages in the exploration, development, production, and marketing of oil and natural gas in the shallow waters of the Gulf of Mexico and onshore in the Gulf Coast area of the United States. It is involved in lifting oil and natural gas to the surface; and gathering, treating, and processing hydrocarbons to extract liquids, such as ethane, propane, butane, and natural gasolines from natural gas. The company also provides exploration and production technologies, including the incorporation of 3-D seismic interpretation, offshore drilling to total depths, and horizontal drilling. As of December 31, 2012, it owned or controlled interests in 1,003 oil and gas leases in the Gulf of Mexico, and onshore Louisiana and Texas covering approximately 511,000 net acres. The company had estimated proved oil and natural gas reserves totaling 219.9 billion cubic feet equivalent. McMoRan Exploration Co. was founded in 1994 and is headquartered in New Orleans, Louisi ana.
Advisors' Opinion:- [By Rich Duprey]
While there was a lot of grousing, the miner was returning to its roots as a multiline resources company -- it will also be purchasing McMoRan Exploration (NYSE: MMR ) , a driller it had spun out in the 1990s -- after a series of mishaps and deadly accidents at its huge Grasberg mine, it could be the drilling operations that Freeport relies upon to see it through.
- [By David Smith]
The pending purchases
Aside from its current core metals operations, Freeport is in the process of acquiring a pair of independent oil and gas producers, Plains Exploration & Production (NYSE: PXP ) and McMoRan Exploration (NYSE: MMR ) . In December, Freeport announced that it would pay 0.6531 shares of its common stock and $25 in cash for each outstanding share of Plains. In addition, for McMoRan it stated that it would pay $14.75 in cash and 1.15 units of a royalty trust that will hold a 5% overriding royalty interest in McMoRan's shallow water and ultra-deepwater prospects. - [By David Smith]
As we move into June, the company's attention is being directed to the combination of starting its huge Grasberg copper and gold facility in Indonesia, following a pair of accidents, and buttoning up its purchase of Houston-based energy producer Plains Exploration and Production Company. At the same time, its preparing to close on its planned acquisition of McMoRan Exploration (NYSE: MMR ) , an event that's expected to occur early next week.
Best Mid Cap Companies To Own In Right Now: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Keith Speights]
This rapid rise stems from investor excitement that Prosensa's drisapersen received breakthrough therapy designation from the Food and Drug Administration. The FDA's move could allow Prosensa and its partner GlaxoSmithKline (NYSE: GSK ) to beat Sarepta Therapeutics (NASDAQ: SRPT ) in the race to bring a Duchenne muscular dystrophy drug to market first.
- [By Keith Speights]
Sometimes, even the hint of an unfavorable regulatory decision can impact a biotech stock. Sarepta Therapeutics (NASDAQ: SRPT ) shares lost more than 25% of their value in April. There wasn't an outright adverse FDA decision in this case. Instead, the FDA requested additional information related to a potential accelerated approval for Duchenne muscular dystrophy drug eteplirsen.
- [By Jake L'Ecuyer]
Sarepta Therapeutics (NASDAQ: SRPT) tumbled 11.94 percent to $18.00 after Citigroup downgraded the stock from Neutral to Sell.
First Solar (NASDAQ: FSLR) was down, falling 9.45 percent to $51.38 after Goldman Sachs downgraded the stock from Buy to Sell.
- [By Roberto Pedone]
One name that's starting to trend within range of triggering a big breakout trade is Sarepta Therapeutics (SRPT), which discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen. This stock has been uptrending strong so far in 2013, with shares up 45%.
If you take a look at the chart for Sarepta Therapeutics, you'll notice that this stock has been uptrending strong over the last month, with shares moving higher from its low of $29.71 to its intraday high of $38.16 a share. During that uptrend, shares of SRPT have been consistently making higher lows and higher highs, which is bullish technical price action. Shares of SRPT have now started to spike back above its 50-day moving average of $37.50, and that move is quickly pushing SRPT within range of triggering a big breakout trade.
Traders should now look for long-biased trades in SRPT if it manages to break out above its 50-day at $37.50 a share and then once it clears some key near-term overhead resistance at $39.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 1.65 million shares. If that breakout hits soon, then SRPT will set up to re-test or possibly take out its next major overhead resistance levels at $46 to $47 a share.
Traders can look to buy SRPT off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $35.31 to $35 a share. One can also buy SRPT off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Best Mid Cap Companies To Own In Right Now: Scorpio Tankers Inc.(STNG)
Scorpio Tankers Inc. provides marine transportation of crude oil and refined petroleum products worldwide. As of April 26, 2011, it owned one LR2 tanker, four LR1 tankers, four Handymax tankers, and one post-Panamax tanker, as well as chartered one LR1 and four Handymax product tankers. The company was founded in 2009 and is based in Monaco, Monaco.
Advisors' Opinion:- [By Seth Jayson]
Scorpio Tankers (NYSE: STNG ) reported earnings on July 29. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Scorpio Tankers missed estimates on revenues and missed estimates on earnings per share. - [By Seth Jayson]
Scorpio Tankers (NYSE: STNG ) reported earnings on April 29. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Scorpio Tankers missed estimates on revenues and beat expectations on earnings per share.
Best Mid Cap Companies To Own In Right Now: Rosetta Stone(RST)
Rosetta Stone Inc., together with its subsidiaries, provides technology-based language-learning solutions in the United States and internationally. The company develops, markets, and sells language-learning solutions, such as software, online services, mobile applications, and audio practice tools in approximately 30 languages primarily under the Rosetta Stone brand. Its products and services include Rosetta Course, a self-study interactive language-learning curriculum that consists of sequences of listening, speaking, reading, and writing interactions designed to teach, reinforce, and test learners through its software program; Rosetta Studio comprising a series of coach-led practice sessions that provide learners to practice what they have previously learned through the software program; and Rosetta World, an interactive community of language learners, which gives learners the opportunity to play games with other learners. The company also offers Audio Companion, which i s a series of digital audio files that contain lessons aligned to the Rosetta Stone curriculum, allowing users to practice previously learned material; and TOTALe Companion HD, a learning tool that includes a series of practice lessons, which use images, audio, and speech recognition technology to enable users refine their speaking skills. The company also offers SharedTalk, an online peer-to-peer practice environment at sharedtalk.com; and ReFLEX, a solution designed for English learners who want to enhance listening and speaking skills. Rosetta Stone sells its products and services through Websites, call centers, retailers, direct sales force, and a network of kiosks. Its customers include individuals, home school parents, educational institutions, armed forces, government agencies, corporations, and not-for-profit institutions. Rosetta Stone Inc. was founded in 1992 and is headquartered in Arlington, Virginia.
Advisors' Opinion:- [By Dan Radovsky]
Rosetta Stone (NYSE: RST ) plans to expand beyond its foreign language learning niche with its proposed acquisition of Lexia Learning Systems, a producer of interactive software to teach English reading skills to young students, Rosetta Stone announced today.
No comments:
Post a Comment